Andarine (GTX-007)
CAS NO: No data
Molecular weight: No data
EC NO: No data
Molecular formula: No data
InChI: No data
Specifications: No data
Packing: No data
Nickname: No data
Product Uses
Foshan Xinhang Biological Technology Co., Ltd.

foshanshi,guangdong,China

Member Since: 0

17725670492

Contact factory

Send your message to this FactoryX

Send
XProduct Details

morgan@chembj.com,

whatapp:+86 17725670492


hi,dear friend

welcome to our online shop

if you want buy high purity pharm raws with competive price and safe delivery

Congratulations because you get the right place!

pls feel free to contact us to find what you real need

we are glad to help.


Andarine (GTX-007)

 

Product Name: Andarine 

Synonyms: sarM s4 

CAS: 401900-40-1 

MF: C19H18F3N3O6 

MW: 441.36 

Chemical Properties Pale Yellow Solid 

Usage It is a potent and tissue-selective androgen receptor modulator (SARM) 

More detial:

S4 (ANDARINE) is a SARM that was developed for treatment of muscle wasting, osteoporosis and benign prostatic hypertrophy. S4 is effective in not only maintaining lean body mass, but increasing it while reducing body fat.

 

The way that S4 works is by binding to the androgen receptor demonstrating bone and muscular anabolic activity. By binding to the androgen receptors, S4 alters the expression of genes and increases protein synthesis. This leads to the building of quality muscle. S4 can produce muscle growth as steroids do without the type of side effects that steroids produce.

Usage:

Andarine (GTx-007, S-4) is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy, using the non-steroidal androgen antagonist bicalutamide as a lead compound.


Andarine is an orally active partial agonist for androgen receptors. It is less potent in both anabolic and androgenic effects than other SARMs. In an animal model of benign prostatic hypertrophy, andarine was shown to reduce prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects.


This suggests that it is able to competitively block binding to its receptor targets in the prostate gland, but its partial agonist effects at androgen receptors prevent the side effects associated with the anti-androgenic drugs traditionally used for treatment of BPH.

morgan@chembj.com,

whatapp:+86 17725670492


Contact factory